Epratuzumab Tesirine

• UNSPSC Description:

  Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG3249[1].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs)

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/epratuzumab-tesirine.html

• Smiles:

  [Epratuzumab Tesirine]

• References & Citations:

  [1]Francesca Zammarchi, et al. ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Mol Cancer Ther. 2024 Apr 2;23(4):520-531.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2